NEUMOLOGÍA PEDIÁTRICA

20 / 31

Neumol Pediatr 2016; 11 (1) Sup: S5-S19
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl S18
Consenso chileno SER-SOCHINEP para el manejo del asma severo en el niño
inflammation and clinical outcomes in overcomes in overweight
and obese asthma: a randomized trial. Clin Exp Allergy
2013;43:36-49.
23. Morgan MD. Dysfunctional breathing in asthma: is it
common, identifiable and correctable? Thorax 2002; 57 (Suppl
2): ii31–ii35.
24. Brouwer AF, Roorda RJ, Brand PL. Treatment of asthma in
children: more than merely ‘‘puffing’’. Ned Tijdschr Geneeskd
2004; 148: 865–8.
25. de Groot EP, Duiverman EJ and Brand PL. Comorbidities of
asthma during childhood possibly important, yet poorly studied.
Eur Respir J 2010: 36:671-8.
26. Simpson AB, Glutting J, Yousef E. Food allergy and asthma
morbidity in children. Pediatr Pulmonol 2007; 42: 489–95.
27. Katon WJ, Richardson L, Russo J, Lozano P, McCauley E.
Quality of mental health care for youth with asthma and comorbid
anxiety and depression. Med Care 2006; 44: 1064–72.
28. Jentzsch NS, Camargos P, Sarinho ES, Bousquet J. Adherence
rate to beclomethasone dipropionate and the level of asthma
control. Respir Med 2012; 106: 338-43.
29. Morton RW, Everard ML, Elphic HE. Adherence in childhood
asthma: the elephant in the room. Arch Dis Child 2014; 99: 949-
53.
30. Klok T, Kaptein AA, Duivermann EJ, Brand PL. It´s the
adherence, stupid (that determines asthma control in preschool
children). Eur Respir J 2014; 43: 783-91.
31. Navarro M, Perez G, Romero M. Causas de asma de control
difícil (ACD). Factores que pueden agravar el asma. An Pediatr
(Barc) 2005; 62(Supl 1): 35-40.
32. Klok T, Kaptein AA, Brand PL. Non-adherence in children with
asthma reviewed: The need for improvement of asthma care and
medical education. Pediatr Allergy Immunol 2015; 26: 197-205.
33. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern
J, Lemanske R, et al. International consensus on (ICON) pediatric
asthma. Allergy 2012; 67:976-97.
34. Consenso SEPAR-ALAT sobre terapia inhalada. Arch
Bronconeumol 2013;49(Supl 1):2-14.
35. Laube BL, Janssens HM , Jongh FHC, Devadason SG, Dhand
R, Diot P, et al. What the pulmonary specialist should know about
the new inhalation therapies. Eur Respir J 2011; 37: 1308–14.
36. Ruedas S . Sistemas de inhalación en el asma infantil. An
Pediatr Contin 2012; 10: 148-57.
37. Kanchongkittiphon W, Mendell MJ, Gaffin JM, Wang
G, Phipatanakul W. Indoor environmental exposures and
exacerbation of asthma: an update to the 2000 review by the
Institute of Medicine. Environ Health Perspect 2015; 123: 6-20.
38. Saglani S, Fleming L . How to manage a child with difficult
asthma? Expert Rev Respir Med. 2016; 2: 1-7.
39. Milligan KL, Matsui E, Sharma H. Asthma in Urban Children:
Epidemiology, Environmental Risk Factors, and the Public Health
Domain. Curr Allergy Asthma Rep 2016; 16:33.
40. Evaluación de impacto atmosférico de sistemas de calefacción
domiciliaria. Centro Nacional del Medio Ambiente. CENMA. Junio
2011. Disponible en:
-glp-chile#.V1RAc1jlHEM.gmail
41. Dean AJ, Walters J, Hall A. A systematic review of interventions
to enhance medication adherence in children and adolescents
with chronic illness. Arch Dis Child 2010; 95: 717–23.
42. Holgate ST. New strategies with anti-IgE in allergic diseases.
World Allergy Organization Journal 2014; 7: 17.
43. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T,
Barberi S, et al. Omalizumab in children. Paediatr Drugs 2014;
16: 491–502.
44. Roth M, Zhao F, Zhong J, Lardinois D, Tamm M. Serum IgE
induced airway smooth muscle cell remodeling is independent
of allergens and is prevented by omalizumab. PLoS One 2015;
10: e0136549.
45. Normansell R, Walker S, Milan SJ, Walters EH, Nair P.
Omalizumab for asthma in adults and children. Cochrane
Database Syst Rev 2014 Jan 13; (1): CD003559.
46. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and
safety of subcutaneous omalizumab vs placebo as add-on
therapy to corticosteroids for children and adults with asthma: a
systematic review. Chest 2011; 139:28–35.
47. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G,
Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness
of omalizumab in allergic asthma. Respir Med 2013; 107: 1141-
51.
48. Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J,
Erpenbeck VJ. Omalizumab in asthma: an update on recent
developments. J Allergy Clin Immunol Pract 2014; 2: 525-36.
49. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet
J. Benefits of omalizumab as add-on therapy in patients with
severe persistent asthma who are inadequately controlled
despite best available therapy (GINA 2002 step 4 treatment):
INNOVATE. Allergy 2005: 60: 309–16.